Last $11.87 USD
Change Today -0.09 / -0.75%
Volume 820.6K
As of 5:20 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Key Developments

Nektar Therapeutics Approves Amendment and Restatement of the Amended and Restated Bylaws

On April 11, 2014, the board of directors of Nektar Therapeutics approved the amendment and restatement of the Amended and Restated Bylaws of the company, effective as of April 11, 2014, to include a new provision in Article XV, Section 47 to provide for exclusive jurisdiction of the Delaware courts for adjudicating disputes. The new provision provides that unless the company consents in writing to the selection of an alternative forum; the Court of Chancery of the State of Delaware; the Superior Court of the State of Delaware if the Court of Chancery of the State of Delaware lacks jurisdiction, or the United States District Court of the District of Delaware if the Superior Court of the State of Delaware lacks jurisdiction (collectively, the "Delaware Court") shall be the sole and exclusive forum for the following actions: any derivative action or proceeding brought on behalf of the company; any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the company to the company or the company's stockholders; any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or the company's certificate of incorporation or the Bylaws; any action to interpret, enforce or determine the validity of the company's certificate of incorporation or the Bylaws; or any action asserting a claim governed by the internal affairs doctrine. Any person purchasing or otherwise acquiring any interest in shares of capital stock of the company shall be deemed to have notice of and consented to the above provision. In addition, if any action, the subject matter of which is within the scope of the above provision, is filed in a court other than the Delaware Court in the name of any stockholder of the company (a "Foreign Action"), such stockholder shall be deemed to have consented to the personal jurisdiction of the Delaware Court in connection with any action brought in any Delaware Court to enforce the above provision and having service of process made upon such stockholder in any such enforcement action by service upon such stockholder's counsel in the Foreign Action as agent for such stockholder.

Nektar Therapeutics Announces Positive Preclinical Data from Breast and Colon Cancer Studies

Nektar Therapeutics announced preclinical data from studies with NKTR-102 and NKTR-214, in models with breast and colon cancer. Positive preclinical data was presented for NKTR-102 (etirinotecan pegol), a novel, next-generation topoisomerase I inhibitor, which is currently in Phase III development for the treatment of advanced breast cancer. In a model of triple-negative breast cancer with brain metastases (MDA-MB-231Br cell line), NKTR-102 reduced the size and number of brain metastases and also prolonged survival as compared to both placebo and irinotecan, a first-generation topoisomerase-I inhibitor.

Nektar Therapeutics Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 08:00 AM

Nektar Therapeutics Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 08:00 AM. Venue: The Westin Grand Central Hotel, New York, New York, United States.

Nektar Therapeutics Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Nektar Therapeutics reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported total revenue of $31,146,000 compared to $21,146,000 a year ago. Loss from operations was $35,894,000 compared to $43,381,000 a year ago. Loss before provision for income taxes was $46,024,000 compared to $52,959,000 a year ago. Net loss was $47,659,000 compared to $52,926,000 a year ago. Basic and diluted net loss per share was $0.41 compared to $0.46 a year ago. For the full year, the company reported total revenue of $148,921,000 compared to $81,191,000 a year ago. Loss from operations was $120,130,000 compared to $141,201,000 a year ago. Loss before provision for income taxes was $159,768,000 compared to $171,449,000 a year ago. Net loss was $162,013,000 compared to $171,855,000 a year ago. Basic and diluted net loss per share was $1.40 compared to $1.50 a year ago. Net cash used in operating activities was $38,527,000 compared to $129,756,000 a year ago. Purchases of property and equipment were $4,091,000 compared to $10,583,000 a year ago.

Nektar Therapeutics Presents at 26th Annual ROTH Conference, Mar-10-2014 11:30 AM

Nektar Therapeutics Presents at 26th Annual ROTH Conference, Mar-10-2014 11:30 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.87 USD -0.09

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $14.28 USD +1.07
Inovio Pharmaceuticals Inc $2.60 USD -0.01
Ironwood Pharmaceuticals Inc $12.01 USD +0.23
Pacira Pharmaceuticals Inc/DE $67.78 USD -0.52
Skyepharma PLC 235.00 GBp +5.00
View Industry Companies
 

Industry Analysis

NKTR

Industry Average

Valuation NKTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.